Filtered By:
Specialty: Drugs & Pharmacology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 688 results found since Jan 2013.
Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min
In conclusion, the 25% increase in edoxaban dose (60-75 mg) resulted in ≈25% exposure increase in the 75-mg group. Higher exposure was not associated with reduced stroke risk in patients with AF with high renal clearance.
Source: Clinical Pharmacology in Drug Development - December 8, 2021 Category: Drugs & Pharmacology Authors: Ophelia Yin,
Tarundeep Kakkar,
Anil Duggal,
Masakatsu Kotsuma,
Minggao Shi,
Hans Lanz,
Michael A. Grosso Tags: Original Article Source Type: research
Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 25, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane,
Juan Carlo O. Avalon,
Jordan L. Lacoste,
Wei Fang,
Christopher M. Bianco,
Laura Davisson,
Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Biotechnology-based therapeutics for management of cerebral stroke
Eur J Pharmacol. 2021 Nov 18:174638. doi: 10.1016/j.ejphar.2021.174638. Online ahead of print.ABSTRACTCerebral stroke, commonly caused due to hindrance in blood flow, is broadly classified into two categories-ischemic and haemorrhagic strokes. The onset of stroke triggers multiple mechanisms causing inflammation, generation of free radicals and protein damage leading to apoptosis of neuronal cells. The current therapies available for cerebral strokes involve use of complex surgical treatments and tissue plasminogen activator which increases the risk of internal bleeding, brain edema and cerebral damage, thereby restricting...
Source: European Journal of Pharmacology - November 21, 2021 Category: Drugs & Pharmacology Authors: Dhrumi Patel Sarika Wairkar Source Type: research
Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis
ConclusionsCombination therapy reduced the incidence of MI in ACS patients, but the risk of bleeding from intracranial hemorrhaging outweighs the benefit of MACE driven by MI. That is due to combination therapy having no positive impact on mortality; thus, the benefit –risk balance may be more favorable in patients with stable CAD.
Source: Drugs - November 3, 2021 Category: Drugs & Pharmacology Source Type: research
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
This article is protected by copyright. All rights reserved.PMID:34671983 | DOI:10.1002/jcph.1988
Source: The Journal of Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Dimitri P Mikhailidis Antonis S Manolis Source Type: research
Feasibility and usability of a mobile health tool on anticoagulation management for patients with atrial fibrillation: a pilot study
ConclusionOverall, the anticoagulation management model developed in this study could be involved in the full process of anticoagulation therapy in AF patients to improve rationality, adherence, and satisfaction in both medical professionals and patients. However, the usability, feasibility, and acceptability of the I-Anticoagulant-based anticoagulation management model need to be further assessed through well-designed random clinical trials.
Source: European Journal of Clinical Pharmacology - October 20, 2021 Category: Drugs & Pharmacology Source Type: research
Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis
ConclusionsDabigatran has a favorable impact on effectiveness and safety outcomes compared with vitamin K antagonists in real-world populations.
Source: Clinical Drug Investigation - October 13, 2021 Category: Drugs & Pharmacology Source Type: research
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China
ConclusionTailored DAPT based on the PRiS could assist in improving the prognosis of patients undergoing DES implantation. Further randomized controlled trials are required to provide more evidence for PRiS-guided DAPT.
Source: European Journal of Clinical Pharmacology - October 12, 2021 Category: Drugs & Pharmacology Source Type: research
